MCRB — Seres Therapeutics, Inc.

Summary of MCRB Q3 2025 Earnings Call

1. Key Financial Results and Metrics

• Net Income: Reported net income from continuing operations of $8.2 million, a significant improvement from a net loss of $51 million in Q3 2024.
• Loss from Operations: $22.5 million, offset by a $27.2 million gain from the sale of VOWST, primarily due to a $25 million installment payment from Nestlé.
• R&D Expenses: Decreased to $12.6 million from $16.5 million in Q3 2024, attributed to lower personnel costs and reduced clinical expenses.
• G&A Expenses: Fell to $9.5 million from $12.7 million in the prior year, driven by lower personnel and IT-related expenses.
• Cash Position: As of September 30, 2025, Seres had $47.6 million in cash and equivalents, with an expectation to fund operations through the second quarter of 2026.

2. Strategic Updates and Business Highlights

• SER-155 Development: The company is advancing SER-155 into a Phase II study for preventing bloodstream infections in allo-HSCT patients, with promising Phase Ib results showing a 77% relative risk reduction in infections.
• FDA Feedback: Received constructive feedback from the FDA, aligning on key study parameters for the Phase II protocol, which has Breakthrough Therapy designation.
• Expansion Potential: SER-155 is expected to have applications in other vulnerable patient populations, representing a multibillion-dollar market opportunity.
• Non-Dilutive Funding: Secured a $3.6 million grant from CARB-X to support the development of an oral liquid formulation of SER-155, enhancing access for patients who cannot swallow capsules.
• Investigator-Sponsored Study: Ongoing study at Memorial Sloan Kettering Cancer Center evaluating SER-155 for immune-related enterocolitis, with initial results expected in early 2026.

3. Forward Guidance and Outlook

• Clinical Results Timeline: Anticipate obtaining meaningful interim analysis results from the Phase II study within 12 months of initiation, funding dependent.
• Capital Needs: The company is actively seeking partnerships and capital to support SER-155's development and broader portfolio initiatives.

4. Bad News, Challenges, or Points of Concern

• Workforce Reduction: Implemented a 25% workforce reduction as part of targeted cost-cutting measures to extend cash runway and focus on core priorities.
• Funding Uncertainty: While the company is focused on securing capital, there is no specific guidance on the amount needed to reach the initial SER-155 data, raising concerns about financial stability.
• Market Competition: The potential for competitive pressures in the biotherapeutic space, particularly as the company seeks to expand its offerings.

5. Notable Q&A Insights

• Study Design Discussion: Management provided details on the Phase I study for immune checkpoint-related enterocolitis, emphasizing the significant unmet need and potential patient impact.
• Commercial Opportunity: Highlighted the substantial market for SER-155 in treating complications from immune checkpoint inhibitors, with a focus on the growing sales of related therapies.
• Partnerships and Capital: Management reiterated the importance of securing partnerships or capital but did not provide specifics on current negotiations or timelines.
• Rumors on Acquisition: Management declined to comment on reports of a takeout offer from Nestlé, maintaining a stance of not discussing rumors.

Overall, Seres Therapeutics demonstrated notable financial improvement and strategic progress with SER-155, while facing challenges related to funding and operational adjustments.